Search This Blog

Monday, August 10, 2026

Axsome Q2 2026 revenue rises 44%, EPS misses, FDA accepts AXS-12 narcolepsy NDA

 

Axsome Q2 2026 revenue rises 44% to $216.4M as EPS -$0.99 misses estimates and FDA accepts AXS-12 narcolepsy NDA

  • Non-GAAP EPS was -$0.99 in Q2 2026, down 2% year over year.
  • Q2 2026 revenue of $216.4M increased 44% YoY, below the $224.5M analyst revenue estimate.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)